Key result
Pathogenic variants of the ELAC2 gene were associated with a rare variant of hypertrophic cardiomyopathy with a fatal outcome in the first year of life.
Why the study?
Pathogenic variants of the ELAC2 gene are linked to heterogeneous phenotypes and severe cardiomyopathy with unfavorable prognosis in the first year of life, but clinical observations remain scarce.
Case Report (n=1)
This case report highlights a rare, fatal infantile hypertrophic cardiomyopathy associated with specific ELAC2 gene variants, representing the first such observation in Russia.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for ELAC2 variants in fatal infantile HCM; prospective studies needed to confirm pathogenicity and guide management.
The few foreign papers of the last decade have shown the relationship of various pathogenic variants of the ELAC2 gene to heterogeneous phenotypic manifestations, for which the unfavorable prognosis is common, caused by severe cardiomyopathy in the first year of life. The article presents the first clinical observation of a rare variant of the hypertrophic phenotype cardiomyopathy with a fatal outcome in the first year of life, and variants c.887T>C, p.L296P and c.1979A>T, p.K660I of the ELAC2 gene in Russia. The purpose of the work is to present clinical observation of a child with an early manifestation of a hypertrophic phenotype of cardiomyopathy caused by pathogenic variants of the ELAC2 gene.
No takes yet. Share an insight, caveat, or question.
Гандаева et al. (2022) conducted a case report in Hypertrophic phenotype cardiomyopathy (n=1). Pathogenic variants of the ELAC2 gene (c.887T>C, p.L296P and c.1979A>T, p.K660I) was evaluated on Fatal outcome in the first year of life. Pathogenic variants of the ELAC2 gene were associated with a rare variant of hypertrophic cardiomyopathy with a fatal outcome in the first year of life.
Synapse has enriched 10 related papers. Consider them for comparative context: